Plus Therapeutics Announces Formation of Scientific Advisory Board
November 05 2020 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage company focused on making a positive impact on
patients’ lives, today announced the formation of a Scientific
Advisory Board (SAB) with the appointment of leading experts in the
fields of neuro-oncology, preclinical drug development, and
nanotechnology. The SAB will guide and advise the Company as it
advances its proprietary and versatile nanotechnology platform
developing innovative chemotherapeutics and radiotherapeutics for
rare cancers that address unmet medical needs.
“We are proud to have an accomplished and
diverse group of scientific and clinical experts as inaugural
members of our Scientific Advisory Board,” said Marc Hedrick, M.D.,
President and Chief Executive Officer of Plus Therapeutics. “Their
scientific perspectives will provide value in supporting the
advancement of Plus’ scientific programs, including our lead
investigational drug, Rhenium NanoLiposomes (RNL™) for the
treatment of recurrent glioblastoma, to help improve outcomes for
patients. Our management team is eager to leverage this group’s
expertise to optimize our R&D and clinical
activities.” Founding
members of the SAB include:
Andrew Brenner, M.D.,
Ph.D. – Dr. Brenner is a
medical oncologist and tumor biologist with a focus in drug
development for the management of primary brain tumors and breast
neoplasms. His interests are in developing novel therapeutics for
the treatment of malignancy with a focus on overcoming resistance
to conventional therapeutics. This experience includes navigation
of regulatory processes including IND enabling studies, authoring
study protocols, coordinating multicenter studies, as well as
acting as principal investigator of 14 industry and
investigator-initiated Phase 1 trials since 2008. Dr. Brenner
earned his bachelor’s degree in biochemistry and went on to earn
his doctorate in biological science and tumor biology at The
University of Texas M.D. Anderson Cancer Center - Science Park. He
received his medical degree from the Texas Tech University Health
Science Center and completed a residency in internal medicine at
Scott and White Hospital in Lubbock, Texas. He completed his
fellowship in hematology and medical oncology at the UT Health San
Antonio.
John
McKew, Ph.D. –
Dr. McKew has 27 years of experience developing novel therapeutics
where he successfully advanced therapies through preclinical and
into clinical development. He is currently Chief Operating Officer
of Lumos Pharma. Prior to Lumos Pharma, Dr. McKew was Vice
President of Research at aTyr Pharma where he led a research team
discovering and advancing protein-based therapeutics for rare
diseases. He has also served as Acting Scientific Director for the
National Center for Advancing Translational Science (NCATS)
intramural group, a part of the National Institute of Health (NIH).
At NCATS, his lab’s work on rare diseases and public/private
partnerships led to the collaborative advancement of several
therapeutic candidates currently being commercialized by
pharmaceutical companies. Dr. McKew is also an Adjunct Professor at
the Boston University School of Medicine and has previously served
as the Chair Elect, Chair and Immediate Past Chair of the American
Chemical Society’s Northeastern section. He has over 70
peer-reviewed publications and granted patents. Dr. McKew graduated
from State University of New York at Stony Brook with B.S. degrees
in Chemistry and Biochemistry, completed his Ph.D. in Organic
Chemistry at University of California, Davis and held post-doctoral
research positions at the University of Geneva and Firmenich,
SA.
Vladimir P.
Torchilin, Ph.D., D.Sc. – Dr.
Torchilin is a University Distinguished Professor and Director,
Center for Pharmaceutical Biotechnology and Nanomedicine,
Northeastern University, Boston. He obtained a M.S. in Chemistry as
well as a Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of
Physiologically Active Compounds from Moscow University. In 1991,
Dr. Torchilin joined MGH/Harvard Medical School as the Head of
Chemistry Program, Center for Imaging and Pharmaceutical Research,
and Associate Professor of Radiology. Since 1998 Dr. Torchilin has
been with Northeastern University, including as the Chair of the
Department of Pharmaceutical Sciences from 1998-2008. His research
interests include liposomes, lipid-core micelles, biomedical
polymers, drug delivery and targeting, pharmaceutical nanocarriers,
experimental cancer immunology. He has published more than 400
original papers, more than 150 reviews and book chapters, and holds
more than 40 patents. He has also wrote and edited 10 books,
including Immobilized Enzymes in Medicine, The Handbook on Targeted
Delivery of Imaging Agents, Liposomes: A Practical Approach,
Nanoparticulates as Pharmaceutical Carriers, Multifunctional
Pharmaceutical Nanocarriers, Biomedical Aspects of Drug Targeting,
Delivery of Protein and Peptide Drugs in Cancer.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at plustherapeutics.com and
respect-trials.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter VozzoWestwicke/ICR(443) 377-4767
Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024